Rigel Tumbles on Phase II RA Failure; Lilly Drug Misses, Too
AstraZeneca plc's top-line results from a Phase IIb study of fostamatinib in rheumatoid arthritis (RA) showed that the drug was superior to placebo at six weeks, but it fell short of a secondary goal of noninferiority against Humira (adalimumab, Abbott), sending shares of partner Rigel Pharmaceuticals Inc., of South San Francisco, plunging by almost 35 percent.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter